Taxifolin (Flavanonol) — Hermetica Encyclopedia
Named Bioactive Compounds · Compound

Taxifolin (Flavanonol)

Moderate Evidenceflavonoid5 PubMed Studies

Hermetica Superfood Encyclopedia

The Short Answer

Taxifolin is a flavanonol compound found in milk thistle and larch trees that functions as a potent antioxidant and anti-inflammatory agent. This bioactive flavonoid crosses the blood-brain barrier and may help reduce amyloid-beta protein accumulation associated with cognitive decline.

5
PubMed Studies
0
Validated Benefits
Synergy Pairings
At a Glance
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordtaxifolin benefits
Synergy Pairings3
Taxifolin close-up macro showing natural texture and detail — rich in antioxidant, anti-inflammatory, cardioprotective
Taxifolin (Flavanonol) — botanical close-up

Health Benefits

Origin & History

Taxifolin growing in natural environment — natural habitat
Natural habitat

Taxifolin is a flavanonol, a subclass of flavonoids within the polyphenol family, naturally occurring in various plants including pine needles from Larix species, cedar, other conifers, as well as fruits like apples and grapes. Commercial extraction typically involves solvent extraction from plant sources such as larch wood or pine bark, followed by purification to isolate the compound.

No information on traditional or historical medicinal uses of taxifolin is available in the current research. The compound's therapeutic investigation appears to be a modern scientific endeavor.Traditional Medicine

Scientific Research

The primary human evidence comes from the ongoing T-COG trial (PMID: 41158654), a randomized, double-blind, placebo-controlled crossover study testing 100mg daily taxifolin in 60 patients with mild cognitive impairment or mild dementia over 12 weeks. One case report (n=1) documented improvements in a 42-year-old man with cerebral amyloid angiopathy, showing 22-24% reductions in brain amyloid deposition. No completed human RCTs or meta-analyses are available.

Preparation & Dosage

Taxifolin prepared for supplementation — pairs with No synergistic ingredients identified in research
Traditional preparation

The clinically studied dosage in the T-COG trial is 100 mg taxifolin capsules taken orally once daily for 12 weeks. No other dosage forms or ranges have been clinically tested. Consult a healthcare provider before starting any new supplement.

Nutritional Profile

Taxifolin (flavanonol/dihydroquercetin) is a pure bioactive flavonoid compound, not a whole food, so it contains no macronutrients (protein, fat, carbohydrates), fiber, or caloric value in isolated supplemental form. Molecular weight: 304.25 g/mol. Chemical formula: C15H12O7. Bioactive compound concentration in supplements typically ranges from 90-99% purity (standardized extracts, commonly sourced from Siberian larch bark, Larix sibirica). In larch bark raw material, taxifolin content ranges approximately 70-90 mg/g dry weight. In grape seeds and skin, taxifolin occurs at lower concentrations (~0.1-1 mg/g). As a flavanonol, it contains a 3-hydroxyflavanone skeleton with five hydroxyl groups, contributing to its antioxidant activity (ORAC value estimated >6,000 µmol TE/g in isolated form). Bioavailability is considered moderate-to-low due to limited aqueous solubility (~0.5 mg/mL at room temperature); absorption occurs primarily in the small intestine with some colonic microbial metabolism producing phenolic acid metabolites (phloroglucinol, 3,4-dihydroxyphenylacetic acid). Lipid-based or nanoparticle formulations improve bioavailability by an estimated 2-4 fold. No significant vitamin or mineral content is inherent to the isolated compound.

How It Works

Mechanism of Action

Taxifolin exerts its effects through multiple antioxidant pathways, including scavenging reactive oxygen species and chelating metal ions that promote oxidative stress. The compound modulates inflammatory mediators like NF-κB and cyclooxygenase enzymes while supporting mitochondrial function. In brain tissue, taxifolin may interfere with amyloid-beta protein aggregation and promote clearance of these neurotoxic plaques.

Clinical Evidence

Clinical evidence for taxifolin remains limited and preliminary. The ongoing T-COG trial (n=60) is investigating taxifolin's effects on cognitive function in mild cognitive impairment using Montreal Cognitive Assessment scores, but results are not yet available. One case report suggested a 22-24% reduction in brain amyloid-beta deposition, though single case studies provide weak evidence. Most research consists of preclinical studies in cell cultures and animal models rather than human trials.

Safety & Interactions

Taxifolin appears generally well-tolerated based on limited safety data, though comprehensive human safety studies are lacking. No significant drug interactions have been reported, but theoretical interactions may occur with anticoagulant medications due to potential effects on platelet function. Safety during pregnancy and breastfeeding has not been established. Individuals with bleeding disorders should exercise caution due to taxifolin's potential antiplatelet effects.

Synergy Stack

Hermetica Formulation Heuristic

Also Known As

Dihydroquercetin3,3',4',5,7-pentahydroxyflavanoneDHQTaxifoliolDistylin3,5,7,3',4'-pentahydroxyflavanone

Frequently Asked Questions

What foods contain taxifolin naturally?
Taxifolin is found primarily in milk thistle seeds, larch wood (Larix species), and Douglas fir bark. Smaller amounts occur in onions, citrus fruits, and some berries, though concentrations are typically much lower than in tree-derived sources.
How much taxifolin should I take daily?
No standardized dosage exists for taxifolin due to limited clinical research. The ongoing T-COG cognitive trial is testing specific doses, but results aren't published yet. Most supplement products contain 50-200mg per serving, though optimal dosing remains undetermined.
Can taxifolin help with Alzheimer's disease?
While one case report showed reduced brain amyloid-beta levels, this represents very preliminary evidence. The compound's ability to cross the blood-brain barrier is promising, but large-scale clinical trials are needed to establish any benefits for Alzheimer's disease.
Is taxifolin the same as quercetin?
No, taxifolin and quercetin are different flavonoid compounds with distinct chemical structures. Taxifolin is a flavanonol (also called dihydroquercetin) while quercetin is a flavonol, and they have different bioavailability and biological activities despite structural similarities.
Does taxifolin have any side effects?
Reported side effects are minimal in available studies, though comprehensive safety data is limited. Some individuals may experience mild gastrointestinal upset or allergic reactions. Those taking blood-thinning medications should consult healthcare providers due to potential antiplatelet effects.
What is the current evidence quality for taxifolin's effects on cognitive function?
Evidence for taxifolin and cognitive function remains preliminary, primarily based on an ongoing T-COG trial (n=60) measuring effects on Montreal Cognitive Assessment scores in mild cognitive impairment—results are not yet published. While one case report suggested a 22-24% reduction in brain amyloid-beta deposition after 6-10 months, this single-subject finding cannot be generalized. Larger, completed clinical trials are needed before firm conclusions can be drawn about taxifolin's cognitive benefits in humans.
Does taxifolin interact with common medications?
Limited human clinical data exists on taxifolin-medication interactions; most evidence comes from in vitro and animal studies. As a flavonoid with antioxidant and anti-inflammatory properties, taxifolin may theoretically interact with blood thinners, antiplatelet drugs, or medications metabolized by hepatic enzymes, though clinical significance remains unclear. Individuals taking prescription medications should consult a healthcare provider before adding taxifolin supplementation.
Who is most likely to benefit from taxifolin supplementation?
Individuals with mild cognitive impairment may be candidates based on the ongoing T-COG trial, though results are not yet available. Those seeking general neuroprotection or reduction in neuroinflammation may theoretically benefit given taxifolin's antioxidant properties, but evidence in healthy populations is lacking. People with documented amyloid pathology or early cognitive decline should discuss taxifolin use with a neurologist or physician, as clinical evidence remains very limited.

Explore the Full Encyclopedia

7,400+ ingredients researched, verified, and formulated for optimal synergy.

Browse Ingredients
These statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.